Oxytocin to Enhance Integrated Treatment for AUD and PTSD

Completed · Phase 2 · Has a placebo group

Conditions studied: PTSD, Alcohol Use Disorder

In brief

The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure). To evaluate purported neurobiological mechanisms of change, we will employ functional magnetic resonance imaging (fMRI) at pre- and post-treatment.

Key facts

Study ID

NCT04523922

Run by

Medical University of South Carolina

People needed

175

Starts

2021-03-29

Expected to finish

2026-04-13

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female; U.S. military Veteran, any race or ethnicity; aged 18-70 years.
• Able to provide written informed consent.
• Meet DSM-5 diagnostic criteria for current moderate to severe alcohol use disorder.
• Meet DSM-5 diagnostic criteria for current PTSD as assessed by the CAPS-5.
• Participants may also meet criteria for a mood disorder (except bipolar affective disorder, see Exclusion Criteria) or anxiety disorders. Concurrent substance use disorders (e.g., marijuana) are acceptable provided alcohol is the participant's primary substance of choice.
• Participants taking psychotropic medications will be required to be maintained on a stable dose for at least 4 weeks before study initiation.

You may not qualify if…

• Meeting DSM-5 criteria for a history of or current psychotic or bipolar affective disorders, or with current suicidal or homicidal ideation and intent. Those participants will be referred clinically for services.
• Participants on psychotropic medications which have been initiated during the past 4 weeks.
• Acute alcohol withdrawal as indicated by CIWA-Ar scores >8.
• Pregnancy or breastfeeding for women.
• For MRI scan component: history of seizures or severe head injury, implanted metal devices or other metal (e.g., shrapnel). These participants will be eligible to enroll in the clinical trial but will not be eligible to participate in the neuroimaging component of the study.
• Currently enrolled in behavioral treatment for AUD or PTSD.

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.